Girocitinib

Small molecule

Filedunder review

Evidence outlook · regulatory review

Rheumatoid Arthritis: application under NMPA (CDE) review

China's CDE proposes priority review for girocitinib (TLL-018) in rheumatoid arthritis (2026-09-24). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Also in development:PsoriasisChronic Spontaneous Urticaria

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

4 other tracked programmes target this mechanism.

This drug's own stage for Chronic Spontaneous Urticaria: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Girocitinib: this drugStage not on recordSmall moleculeTYK2/JAK1Reliable signalNo reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEPartial signal
NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73)
NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results).
RemibrutinibApprovedSmall moleculeBruton's tyrosine kinase (BTK)Reliable signalNo reviewed efficacy summary in this indication
BarzolvolimabPhase 3Monoclonal antibodyKITPartial signal
NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
BHV-8000
Phase 2/3(overall)
Small moleculeTYK2/JAK1
not yet graded(overall)
No reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
HRS-3095Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TDM-180935
Phase 2(overall)
Small moleculeTYK2/JAK1
Partial signal(overall)
No reviewed efficacy summary in this indication
BriquilimabPhase 1/2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
SAR449028
—(overall)
UndisclosedKITnot yet gradedNo reviewed efficacy summary in this indication
SHR-3095
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 September 2026Priority reviewChina's CDE proposes priority review for girocitinib (TLL-018) in rheumatoid arthritis
CN, NMPA (CDE) · Source ↗
27 April 2026Topline resultPhase 3 RA trial of girocitinib (TLL-018) vs tofacitinib met its primary endpoint (ACR50 at week 24)
CN · Hangzhou Highlightll Pharmaceutical · Source ↗